Cart summary

You have no items in your shopping cart.

Anti-GPC3 / Glypican-3 Reference Antibody (codrituzumab)

Catalog Number: orb1806346

DispatchUsually dispatched within 5-10 working days
$ 80.00
Catalog Numberorb1806346
CategoryAntibodies
DescriptionAnti-GPC3 / Glypican-3 Reference Antibody is expressed from CHO. The heavy chain type is huIgG1, and the light chain type is hukappa. It has a predicted MW of 145.5 kDa.
ClonalityMonoclonal
Tested applicationsELISA, FA, FACS, Kinetics
ReactivityHuman
IsotypeIgG
Purity> 95%
ConjugationUnconjugated
MW150 kDa
TargetGPC3 / Glypican-3
Endotoxins< 1 EU/mg
StorageMaintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.
Buffer/Preservatives100 mM Pro-Ac 20 mM Arg pH 5.0
NoteFor research use only
Expiration Date12 months from date of receipt.
Anti-GPC3 / Glypican-3 Reference Antibody (codrituzumab)

Anti-GPC3 / Glypican-3 Reference Antibody (codrituzumab) on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%.

Anti-GPC3 / Glypican-3 Reference Antibody (codrituzumab)

The purity of Anti-GPC3 / Glypican-3 Reference Antibody (codrituzumab)is more than 95% ;determined by SEC-HPLC.

Anti-GPC3 / Glypican-3 Reference Antibody (codrituzumab)

Immobilized human GPC3; His tag at 2 μg/mL can bind Anti-GPC3 / Glypican-3 Reference Antibody (codrituzumab);EC50=0.008741μg/mL.

Anti-GPC3 / Glypican-3 Reference Antibody (codrituzumab)

Human GPC3 CHOS cells were stained with Anti-GPC3 / Glypican-3 Reference Antibody (codrituzumab) and negative control protein respectively; washed and then followed by PE and analyzed with FACS; EC210=2.142 nM.

Anti-GPC3 / Glypican-3 Reference Antibody (codrituzumab)

The endocytosis ratio codrituzumab by HuH-7 increased with the increase of antibody concentration; and the Internalization Rate (%) reached 40%at antibody concentration of 1 nM.

Anti-GPC3 / Glypican-3 Reference Antibody (codrituzumab)

Anti-GPC3 / Glypican-3 Reference Antibody (Codrituzumab)-induced ADCC activity was evaluated using human GPC3 CHOS Cell. The max Lysis rate was approximately 30%.